Drugs / MMF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT05686746 Comparator | Jun 2022 → Jun 2023 | nephritis, systemic lupus erythematosus | Assiut University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05686746 ↗ |
| Route | Oral | “1000 mg oral daily” NCT05686746 ↗ |